CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishOn 16 November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib, a small-molecule inhibitor of JAK1/2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. In this issue of Blood, Porpaczy et al report findings of a study showing that JAK1/2 inhibitor treatment is associated with an increased risk for aggressive B-cell lymphomas.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Benefits and risks of JAK inhibition |
| Autori: | |
| Data di pubblicazione: | 2018 |
| Rivista: | |
| Abstract: | On 16 November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib, a small-molecule inhibitor of JAK1/2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. In this issue of Blood, Porpaczy et al report findings of a study showing that JAK1/2 inhibitor treatment is associated with an increased risk for aggressive B-cell lymphomas. |
| Handle: | http://hdl.handle.net/11571/1363417 |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
http://hdl.handle.net/11571/1363417
Copyright © 2021